| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/26/2011 | US20110123515 Egln2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases |
| 05/26/2011 | US20110123514 Angiogenin-enriched milk fractions |
| 05/26/2011 | US20110123513 Alkaline phosphatase to reduce or prevent weight gain |
| 05/26/2011 | US20110123512 Method of regulating the heat shock response |
| 05/26/2011 | US20110123511 Method of Suppressing Gene Transcription Through Histone Lysine Methylation |
| 05/26/2011 | US20110123510 Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis |
| 05/26/2011 | US20110123509 Fusion molecules of rationally-designed dna-binding proteins and effector domains |
| 05/26/2011 | US20110123507 Ultra Low Dose Nutraceutical Compositions for Enhancing Sleep Quality and Treating Sleep Disorders |
| 05/26/2011 | US20110123506 Dietary health food composition, package and method of use |
| 05/26/2011 | US20110123505 Method of producing reduced coenzyme q10 and method of stabilizing the same |
| 05/26/2011 | US20110123501 Gut flora and weight management |
| 05/26/2011 | US20110123496 Bismacrocyclic compounds as hepatitis c virus inhibitors |
| 05/26/2011 | US20110123495 Derivatives of pyridone and use thereof |
| 05/26/2011 | US20110123494 Treatment with anti-vegf antibodies |
| 05/26/2011 | US20110123493 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
| 05/26/2011 | US20110123492 Immunity-inducing agent |
| 05/26/2011 | US20110123491 Methods and compositions for immunization against chlamydial infection and disease |
| 05/26/2011 | US20110123490 Heterocyclic antiviral compounds |
| 05/26/2011 | US20110123489 Heterocyclic antiviral compounds |
| 05/26/2011 | US20110123488 Method of Treatment for Cancers Associated with Elevated HER2 Levels |
| 05/26/2011 | US20110123487 Therapeutic agents comprising elastic peptides |
| 05/26/2011 | US20110123486 Methods of treating multiple myeloma and resistant cancers |
| 05/26/2011 | US20110123485 Viral vectors for delivering vaccines for hiv and other infectious diseases |
| 05/26/2011 | US20110123484 Methods and compositions for treating fus1 related disorders |
| 05/26/2011 | US20110123483 Hmgb1 for cancer treatment |
| 05/26/2011 | US20110123482 Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide |
| 05/26/2011 | US20110123481 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
| 05/26/2011 | US20110123480 Chimeric proteins and uses thereof |
| 05/26/2011 | US20110123466 Pharmaceutical and/or cosmetic composition containing an active principle activator of cytochrome c |
| 05/26/2011 | US20110123456 Hollow biodegradable nanospheres and nanoshells for delivery of therapeutic and/or imaging molecules |
| 05/26/2011 | US20110123454 Method for modulating appetite |
| 05/26/2011 | US20110123452 Metal oligomers and polymers and their use in biology and medicine |
| 05/26/2011 | US20110123451 Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin |
| 05/26/2011 | US20110123446 Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates |
| 05/26/2011 | US20110123437 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| 05/26/2011 | US20110123435 Compounds for inhibiting ksp kinesin activity |
| 05/26/2011 | CA2818241A1 Methods for improving oral delivery |
| 05/26/2011 | CA2781672A1 Polypeptide conjugate |
| 05/26/2011 | CA2781666A1 Lipopeptide compositions and related methods |
| 05/26/2011 | CA2781537A1 Recombinant filaggrin polypeptides for cell importation |
| 05/26/2011 | CA2781433A1 Suppression of cancer metastasis |
| 05/26/2011 | CA2781405A1 Melanocortin-1 receptor-specific linear peptides |
| 05/26/2011 | CA2781290A1 Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr) |
| 05/26/2011 | CA2781277A1 Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| 05/26/2011 | CA2781152A1 Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| 05/26/2011 | CA2781099A1 Improved bacterial membrane protein secrection |
| 05/26/2011 | CA2781032A1 Ifny inhibitors in the treatment of motoneuron diseases |
| 05/26/2011 | CA2780949A1 Template-fixed peptidomimetics with ccr10 antagonistic activity |
| 05/26/2011 | CA2780756A1 Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| 05/26/2011 | CA2780554A1 Formulation for hgh and rhigf-1 combination |
| 05/26/2011 | CA2780207A1 Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease |
| 05/26/2011 | CA2779863A1 Peptide protection against ultraviolet light toxicity |
| 05/26/2011 | CA2774094A1 Formulations of daptomycin |
| 05/26/2011 | CA2770340A1 Preventive and/or therapeutic and/or aggravation suppressing agent for human arthritis deformans |
| 05/25/2011 | EP2325337A1 RNA aptamers and methods for identifying the same |
| 05/25/2011 | EP2325317A1 Receptor nucleic acids and polypeptides |
| 05/25/2011 | EP2325316A1 Novel hemopoietin receptor protein, nr10 |
| 05/25/2011 | EP2325313A2 pRNA chimera |
| 05/25/2011 | EP2325302A1 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
| 05/25/2011 | EP2325301A1 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
| 05/25/2011 | EP2325203A2 Cadherin materials and methods |
| 05/25/2011 | EP2325200A1 Sclerostin binding agents |
| 05/25/2011 | EP2325199A1 Sclerostin binding agents |
| 05/25/2011 | EP2325198A1 Compositions and methods for the therapeutic use of an atonal-associated sequence |
| 05/25/2011 | EP2325196A1 Replikin peptides and uses thereof |
| 05/25/2011 | EP2324863A1 Method for producing artificial skin |
| 05/25/2011 | EP2324852A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 05/25/2011 | EP2324851A1 Methods of administering anti-TNFalpha antibodies |
| 05/25/2011 | EP2324849A2 Selective immune down regulation (SIDR) mediated transplantation processes |
| 05/25/2011 | EP2324847A1 Acceleration of wound healing by a tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors |
| 05/25/2011 | EP2324846A1 Use of urease for inhibiting cancer cell growth |
| 05/25/2011 | EP2324845A1 Liquid stabilized protein formulations in coated pharmaceutical containers |
| 05/25/2011 | EP2324844A2 April receptor (BCMA) and uses thereof |
| 05/25/2011 | EP2324843A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 05/25/2011 | EP2324842A1 Immunity-inducing agent |
| 05/25/2011 | EP2324839A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/25/2011 | EP2324834A2 Methods of Increasing Endogenous Erythropoietin (EPO) |
| 05/25/2011 | EP2324065A1 A heparan sulphate which binds bmp2 |
| 05/25/2011 | EP2324058A1 Biological applications of steroid binding domains |
| 05/25/2011 | EP2324044A2 Sting (stimulator of interferon genes), a regulator of innate immune responses |
| 05/25/2011 | EP2323979A1 Treatment or prevention of hepatitis c with immunomodulator compounds |
| 05/25/2011 | EP2323690A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
| 05/25/2011 | EP2323688A2 Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis |
| 05/25/2011 | EP2323687A2 Method of upregulating sorla for the treatment of alzheimer's disease |
| 05/25/2011 | EP2323686A1 Adiponectin for treating pulmonary disease |
| 05/25/2011 | EP2323685A2 Agonists of nr2f6 for immunosuppression |
| 05/25/2011 | EP2323684A2 Use of a pneumococcal p4 peptide for enhancing opsonophagocytosis in response to a pathogen |
| 05/25/2011 | EP2323683A1 Novel use of bacteriocin derived from enterococcus faecalis sl-5 |
| 05/25/2011 | EP2323682A2 Compositions and methods for increasing serum antioxidant concentrations |
| 05/25/2011 | EP2323681A2 Methods for treating viral disorders |
| 05/25/2011 | EP2323680A2 Proteins for use in diagnosing and treating infection and disease |
| 05/25/2011 | EP2323679A2 Clip inhibitors and methods of modulating immune function |
| 05/25/2011 | EP2323678A2 Glucose-dependent insulinotropic polypeptide analogues |
| 05/25/2011 | EP2323676A1 Protein based product from fenugreek seeds that regulates dyslipidemia and obesity, and a process for the preparation thereof |
| 05/25/2011 | EP2323631A1 Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| 05/25/2011 | EP2323626A2 Parenteral composition comprising microspheres with a diameter between 10 and 20 microns |
| 05/25/2011 | EP2323625A2 New composition for the treatment of ecchymotic pigmentations |
| 05/25/2011 | EP2323624A2 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 05/25/2011 | EP2323623A1 Pharmaceutical compositions |
| 05/25/2011 | EP2003969B1 Mature dendritic cell compositions and methods for culturing same |